Special Report
Aurigene Oncology Reports Strong Early Phase One Results For AUR112 In Relapsed And Refractory Lymphomas
Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology, announced initial clinical results...
December 04, 2025 | News
Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
An international survey, spanning Australia, France, Japan, Poland and the UK, has found that many employees experiencing fertility challenges lack support...
November 27, 2025 | Report
The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech
Global pharmaceutical companies are racing to tap China’s new AI-powered biotech platforms to discover drugs faster and cheaper. In 2025, major Weste...
November 27, 2025 | Analysis
Kelun Biotech Reports Strong Phase Three Success for Sac TMT and Keytruda in First Line Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced that the Independent Data Monitoring Committee (IDMC) concluded t...
November 25, 2025 | News
Global Leaders Signal a Confident New Chapter for Cell and Gene Therapy at GenScript Global Forum London 2025
GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, successfully hosted the GenScript Biotech Global Forum ...
November 24, 2025 | News
Mabwell Secures NMPA Approval to Begin Phase II Trial of First-in-Class Anti-IL-11 Antibody for Pathological Scarring
Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that its novel anti‑IL‑11 monoclonal antibody...
November 12, 2025 | News
Bio-Techne and Nucleai Demonstrate Predictive Power of Spatial Biomarkers in Melanoma
Clinical trial data demonstrates how Bio-Techne's spatial biology technology and Nucleai's AI-powered multimodal platforms can identify predictive biomar...
November 05, 2025 | News
Phenomix’s MyPhenome Test Validates GLP-1 Response Prediction Across 88,000 Patients
Studies presented at Obesity Week 2025 validate the test's ability to predict weight-loss response to GLP-1 drugs like semaglutide, including in ...
November 05, 2025 | Report
Novartis Review Reveals Fear of Recurrence as a Major Unmet Need in Breast Cancer Survivorship Across Asia Pacific and the Middle East
A new targeted literature review finds the fear of recurrence a major unmet need in breast cancer survivorship, often found to affect at least two in fiv...
October 31, 2025 | Report
WuXi AppTec Reports RMB32.86 Billion Revenue for First Three Quarters of 2025, Up 18.6% Year-on-Year
Q3 Total Revenue: RMB12.06 Billion, Up 15.3% YoY; Revenue from Continuing Operations[1]Reached RMB12.04 Billion, Up 19.7% YoY Q1-Q3 Total Re...
October 27, 2025 | Company results
ACM Biolabs and National Cancer Centre Singapore Report Encouraging Asia-Based Early Clinical Findings for ACM-CpG Nanoparticle Immunotherapy
ACM Biolabs, a clinical-stage biotechnology company developing next-generation nanoparticle-based immunotherapies, announced encouraging early clinica...
October 23, 2025 | News
AdvanCell’s Lead-212 Radioligand Therapy Shows Strong Safety and Efficacy in Phase 1b Trial for Metastatic Prostate Cancer
Results from the TheraPb Phase 1b dose escalation presented at ESMO 2025 show a promising therapeutic index for 212Pb-ADVC001 in patients with metastat...
October 22, 2025 | News
Aurion Biotech Data Supports Advancing High-Dose AURN001 Regenerative Cell Therapy to Phase 3 Trial in 2026
Data strongly supports advancing high dose AURN001 regenerative cell therapy for patients with corneal endothelial disease to pivotal Phase 3 trial in H1...
October 20, 2025 | News
Daiichi Sankyo and AstraZeneca’s DATROWAY Combination Delivers 68.2% Response and 95.5% Disease Control in First-Line Metastatic Urothelial Cancer
A confirmed objective response rate of 68.2% and a disease control rate of 95.5% was observed with Daiichi Sankyo and AstraZeneca’s DATROWAY in c...
October 20, 2025 | News
Most Read
- The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech
- Top 25 Biotech & Biopharma Leaders in Sustainable Innovation, 2025
- China’s Biopharma Dealmaking Surges in H1 2025, Driven by Record Licensing and Oncology Focus
- Chikungunya in China: How a “Forgotten” Arbovirus Found the Perfect Storm
- How Innovation Gaps in Biopharma Raise New Safety Concerns
- Smart Implants and the Future of Musculoskeletal Injury Treatment
- How Ethical Gaps in Psychiatry Could Undermine Biopharma Progress
- The Evolving Landscape of Women’s Health Innovation in the Asia-Pacific
- Using NLP-Driven Decision Support in Emergency Health Assistance
- Taiwan Steps Into the Global Spotlight With a New Cancer Therapy
- The Role of Unique Device Identification (UDI) in Tracing Medical Device Safety
- The Importance of a Patient’s Mental Health During Clinical Trials
Bio Jobs
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Avantor’s New CEO Ligner Aims to Unlock Global Potential and Deliver Shareholder Value
- AstraZeneca Commits $50 Billion to U.S. Expansion by 2030 in Biggest-Ever Global Investment
- Thermo Fisher, SAMRC, and South Africa’s Department of Science and Innovation Launch CATIR to Nurture Next-Gen Scientists
- Cube Biotech Appoints Former Sartorius CEO Dr. Joachim Kreuzburg to Board of Directors
- FDA’s AI Transition Marks a Turning Point in Drug Review: Industry Faces Pressure to Adapt Amid 20% Workforce Cut
- WuXi XDC Completes Mechanical Build of Singapore Bioconjugate Manufacturing Hub
News
Editor Picks
